Wire · operational-macro
FDA grants accelerated approval to DNA immunotherapy for adult recurrent respiratory ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 2 November 2026 · Fusion42 review
The FDA granted accelerated approval to INOVIO's DNA immunotherapy Voceryq for adults with recurrent respiratory papillomatosis (RRP) to reduce the frequency of surgical excisions. The approval is based on data showing 27% of treated patients required no surgery for 12 months, with continued approval dependent on confirmatory trials planned by 2027.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it.
◆ ◆ The Wire takeaway
You face a new regulatory route to reduce surgery reliance in respiratory papilloma treatment with INOVIO's approved DNA immunotherapy. Prepare to engage with early adoption and align with confirmatory trial outcomes to secure market access.
◆ Coverage
5 sources · 2 Nov 2026
◆ Related on Wire
◆ Topics